Hookipa Pharma declared plans to delist from Nasdaq and liquidate following the sale of its vaccine assets to Gilead Sciences. The immunotherapy biotech cited lack of revenue-generating products as a principal reason, retaining only essential staff for winding down operations. Development of other pipeline candidates, including investigational immunotherapies for KRAS-mutated cancers, was paused earlier in 2025. Hookipa’s decision follows a string of setbacks including a canceled merger and collaboration losses.